Protection of DDAH2 overexpression against homocysteine-induced impairments of DDAH/ADMA/NOS/NO pathway in endothelial cells

Cellular Physiology and Biochemistry

Volumn 30, Issue 6, 2012, Pages 1413-1422

  Liu, Li Hua ^b   Guo, Zheng ^b   Feng, Mei ^b   Wu, Zhong Zu ^b   He, Zhi Min ^a   Xiong, Yan ^a,b  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Asymmetric dimethylarginine; Dimethylarginine dimethylaminohydrolase; Gene transferring; Homocysteine; Nitric oxide

Indexed keywords

DIMETHYLARGININASE; DIMETHYLARGININE DIMETHYLAMINOHYDROLASE 1; DIMETHYLARGININE DIMETHYLAMINOHYDROLASE 2; HOMOCYSTEINE; MESSENGER RNA; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; UNCLASSIFIED DRUG;

ARTICLE; CELL DAMAGE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION;

EID: 84873150528     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000343329     Document Type: Article

References (29)

1. Ceperkovic Z: The role of increased levels of homocysteine in the development of cardiovascular diseases. Med Pregl 2006;59:143-147.
2. Fu YF, Xiong Y, Guo Z: A reduction of endogenous asymmetric dimethylarginine contributes to the effect of captopril on endothelial dysfunction induced by homocysteine in rats. Eur J Pharmacol 2005;508:167-175. (Pubitemid 40169916)
3. Lan TH, Xu ZW, Wang Z, Wu YL, Wu WK, Tan HM: Ginsenoside Rb1 prevents homocysteine-induced endothelial dysfunction via PI3K/Akt activation and PKC inhibition. Biochem Pharmacol 2011;82:148-155.
4. Sydow K, Schwedhelm E, Arakawa N, Bode-Boger SM, Tsikas D, Hornig B, Frolich JC, Boger RH: ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst (e) inemia: effects of L-arginine and B vitamins. Cardiovasc Res 2003;57:244-252. (Pubitemid 36009457)
5. Woodman RJ, Celermajer DE, Thompson PL, Hung J: Folic acid does not improve endothelial function in healthy hyperhomocysteinaemic subjects. Clin Sci (Lond) 2004;106:353-258.
6. Pan Y, Guo LL, Cai LL, Zhu XJ, Shu JL, Liu XL, Jin HM: Homocysteine-lowering therapy does not lead to reduction in cardiovascular outcomes in chronic kidney disease patients: a meta-analysis of randomised, controlled trials. Br J Nutr 2012:108: 400-407.
7. Ye X, Liu X: Summaries of nursing care-related systematic reviews from the Cochrane library: homocysteinelowering interventions for preventing cardiovascular events. J Cardiovasc Nurs 2011;26:168-169.
8. Bønaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K, NORVIT Trial Investigators: Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-1588.
9. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP: Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999;99:3092-3095. (Pubitemid 29289071)
10. Stühlinger MC, Oka RK, Graf EE, Schmölzer I, Upson BM, Kapoor O, Szuba A, Malinow MR, Wascher TC, Pachinger O, Cooke JP: Endothelial dysfunction induced by hyperhomocyst (e) inemia: role of asymmetric dimethylarginine. Circulation 2003;108:933-938. (Pubitemid 37048221)
11. Kajimoto H, Kai H, Aoki H, Yasuoka S, Anegawa T, Aoki Y, Ueda S, Okuda S, Imaizumi T: Inhibition of eNOS phosphorylation mediates endothelial dysfunction in renal failure: new effect of asymmetric dimethylarginine. Kidney Int 2012;81:762-768.
12. Perticone F, Sciacqua A, Maio R, Perticone M, Galiano Leone G, Bruni R, Di Cello S, Pascale A, Talarico G, Greco L, Andreozzi F, Sesti G: Endothelial dysfunction, ADMA and insulin resistance in essential hypertension. Int J Cardiol 2010;142:236-241.
13. Isiklar OO, Barutcuoglu B, Kabaroglu C, Mutaf I, Ozmen D, Bayindir O, Zoghi M, Uluer H: Do cardiac risk factors affect the homocysteine and asymmetric dimethylarginine relationship in patients with coronary artery diseases? Clin Biochem 2012;45:1325-1330.
14. Schwedhelm E, Xanthakis V, Maas R, Sullivan LM, Schulze F, Riederer U, Benndorf RA, Böger RH, Vasan RS: Asymmetric dimethylarginine reference intervals determined with liquid chromatography-tandem mass spectrometry: results from the Framingham offspring cohort. Clin Chem 2009;55:1539-1545.
15. Stühlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP: Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001;104:2569-2575. (Pubitemid 33104795)
16. Hong L, Fast W: Inhibition of human dimethylarginine dimethylaminohydrolase-1 by S-nitroso-L-homocysteine and hydrogen peroxide. Analysis, quantification, and implications for hyperhomocysteinemia. J Biol Chem 2007;282:34684-34692. (Pubitemid 350232428)
17. Rodionov RN, Dayoub H, Lynch CM, Wilson KM, Stevens JW, Murry DJ, Kimoto M, Arning E, Bottiglieri T, Cooke JP, Baumbach GL, Faraci FM, Lentz SR: Overexpression of dimethylarginine dimethylaminohydrolase protects against cerebral vascular effects of hyperhomocysteinemia. Circ Res 2010;106:551-558.
18. Lu CW, Xiong Y, He P: Dimethylarginine dimethylaminohydrolase-2 overexpression improves impaired nitric oxide synthesis of endothelial cells induced by glycated protein. Nitric. Oxide 2007;16:94-103. (Pubitemid 44820889)
19. Yin QF, Fu SH, He P, Xiong Y: Dimethylarginine dimethylaminohydrolase inhibition and asymmetric dimethylarginine accumulation contribute to endothelial dysfunction in rats exposed to glycosylated protein: effects of aminoguanidine. Atherosclerosis 2007;190:53-61. (Pubitemid 44908321)
20. Fabian E, Kickinger A, Wagner KH, Elmadfa I: Homocysteine and asymmetric dimethylarginine in relation to B vitamins in elderly people. Wien Klin Wochenschr 2011;123:496-501.
21. Xu T, Zhang XW, Qu XK, Ye HY, Huang XB, Zhang XP, Hou SK, Wang XF: Treatment of hyperhomocysteinemia and endothelial dysfunction in renal transplant recipients with B vitamins in the Chinese population. J Urol 2008;179:1190-1194.
22. Song Y, Cook NR, Albert CM, Van Denburgh M, Manson JE: Effect of homocysteine-lowering treatment with folic Acid and B vitamins on risk of type 2 diabetes in women: a randomized, controlled trial. Diabetes 2009;58:1921-1928.
23. Bellamy MF, McDowell IF, Ramsey MW, Brownlee M, Bones C, Newcombe RG, Brownlee M, Bones C, Newcombe RG, Lewis MJ: Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation 1998;98:1848-1852. (Pubitemid 28509279)
24. Abdulle AM, Pathan JY, Moussa N, Gariballa S: Association between homocysteine and endothelial dysfunction markers in stroke disease. Nutr Neurosci 2010;13:2-6.
25. Selley ML: Homocysteine increases the production of asymmetric dimethylarginine in cultured neurons. J Neurosci Res 2004;77:90-93. (Pubitemid 38850058)
26. Chen Y, Li Y, Zhang P, Traverse JH, Hou M, Xu X, Kimoto M, Bache RJ: Dimethylarginine dimethylaminohydrolase and endothelial dysfunction in failing hearts. Am J Physiol Heart Circ Physiol 2005;289:H2212-H2219. (Pubitemid 41507375)
27. Pullamsetti S, Kiss L, Ghofrani HA, Voswinckel R, Haredza P, Klepetko W, Voswinckel R, Haredza P, Klepetko W, Aigner C, Fink L, Muyal JP, Weissmann N, Grimminger F, Seeger W, Schermuly RT: Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB J 2005;19:1175-1177. (Pubitemid 40946456)
28. Wang D, Gill PS, Chabrashvili T, Onozato ML, Raggio J, Mendonca M, Dennehy K, Li M, Modlinger P, Leiper J, Vallance P, Adler O, Leone A, Tojo A, Welch WJ, Wilcox CS: Isoform-specific regulation by N (G), N (G) - dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/NO. Circ Res 2007;101:627-35. (Pubitemid 351325880)
29. Hasegawa K, Wakino S, Tatematsu S, Yoshioka K, Homma K, Sugano N, Kimoto M, Hayashi K, Itoh H: Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginie dimethylaminohydrolase2. Circ Res 2007;101:e2-e10. (Pubitemid 47196589)